Recently, it has been shown that SELPLG acts as an immune checkpoint regulator in colorectal cancer [50], head and neck squamous cell carcinoma, and melanoma [51], making it a potential novel therapeutic target for cancer. The gene discussed is SELPLG; the disease is colorectal cancer.